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Severe eosinophilic syndromes related to the administration or use of unsuspected immunogenic substances have been described
previously. Many of these diseases presented initially as clusters or isolated cases. The spanish toxic oil syndrome, the eosinophilia
myalgia syndrome, and nephrogenic systemic fibrosis are examples of such diseases. We describe 2 cases of a severe eosinophilic
syndrome characterized by marked peripheral blood eosinophilia (>15,000 cells/ml), mononeuritis multiplex, and necrotizing
vasculitis which developed in a close temporal association with the recent onset use of nonprescription probiotics. There was no
history of a prior autoimmune disease. Although both cases had prompt response to immunosuppression with rapid resolution of
peripheral blood eosinophilia and accompanying constitutional symptoms, they remained with permanent neurological deficits.
1. Introduction
Probiotics are defined by the World Health Organiza-
tion/Food and Agriculture Organization (WHO/FAO) as
live microorganisms that when administered at appropriate
doses confer a health benefit to the host by regulation of the
gastrointestinal flora [1, 2]. Most frequently, these include
Lactobacillus or Bifidobacterium species as well as a range
of lactic acid producing bacteria. Being considered a dietary
supplement in the USA, the Food and Drug Administration
(FDA) regulation of probiotics is not as strict as that for
prescription drugs [3]. On the other hand, there is an
increased trend in the use of over-the-counter probiotics in
patients with rheumatic diseases based on the belief that their
use can be beneficial for regulating the immune response
beyond the gastrointestinal tract. Whereas the evidence for
these claims is marginal at best, there have been numerous
reports of adverse events following probiotic use includ-
ing bacteremia with Lactobacilli, Saccharomyces Boulardii
fungemia and endocarditis in postoperative patients, as well
as Saccharomyces Cerevisiae fungemia in immunocompro-
mised patients [4–6]. This report describes two patients who
developed a severe eosinophilic syndrome with vasculitis
and mononeuritis multiplex, temporally associated with
probiotic use. Both patients recalled using a new brand of
probiotic between 2 and 4 weeks prior to symptom onset.
2. Case Reports
Case 1. A 55-year-old female with no significant past
medical history, presented with sudden onset of arthralgias,
myalgias, malaise, night sweats, lower extremity weakness,
and paresthesias of 1-week duration. Physical and neuro-
muscular examination revealed bilateral moderate-to-severe
lower extremity weakness, asymmetrical in severity and
predominantly distal with right foot drop. She was found
to have leukocytosis (29,700 cells/mL) with 56% eosinophils
(16,632 cells/mL). Electromyography (EMG) and nerve con-
duction studies revealed mononeuritis multiplex. Right
quadriceps muscle and right sural nerve biopsies performed
before the initiation of IV steroids or cyclophosphamide
showed severe necrotizing eosinophilic vasculitis (Figure 1).
The sural nerve biopsy showed secondary axonal degen-
eration. Examination of bone marrow demonstrated mild
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Figure 1: Case 1 (A and B). (a) Cryostat section of quadriceps muscle stained with hematoxylin and eosin demonstrates a severe
necrotizing vasculitis of an intramuscular arteriole. Intramural fibrinoid necrosis is evident (arrow). Surrounding the vessel are large
numbers of macrophages, lymphocytes, and eosinophils (original magnification 100x). (b) High-magnification image of formalin fixed,
paraﬃn-embedded tissue with an intramuscular vessel demonstrating large numbers of intramural and perivascular eosinophils (original
magnification 400x).
eosinophilia consistent with a reactive process without
evidence of malignancy. Flow cytometry of peripheral blood
cells was negative for phenotypically abnormal cells. She was
treated with IV corticosteroid pulses (methylprednisolone
1 g IV for 3 consecutive days) followed by oral steroids
(prednisone 1mg/Kg/d) with slow titration downward over
10 months and cyclophosphamide 1000mg/m2/month for 6
months, followed by azathioprine 2mg/kg/d after the initial
6 months.
Case 2. A 65-year-old female with a history of inactive
mild episodic asthma, sinusitis, and a remote history of
Hashimoto’s thyroiditis presented with sudden onset of
abdominal pain, left arm weakness, numbness, right foot
drop, diplopia, and profound general malaise. Physical and
neuromuscular examination revealed mild left arm weakness
along with profound distal right lower extremity weakness
and foot drop. No skin lesions were noticed. Laboratory
studies showed leukocytosis of 24,300 cells/mL with severe
eosinophilia of 76% (18,468 cells/mL). EMG and nerve
conduction studies showed evidence of mononeuritis mul-
tiplex and in addition, a mild underlying diﬀuse peripheral
neuropathy. A right quadriceps muscle biopsy performed
1 week after initiation of IV steroids showed necrotizing
vasculitis without eosinophils (Figure 2). By the time the
biopsy was performed, the peripheral blood eosinophilia had
resolved and apparently also the eosinophilic component
of the vasculitis. A right sural nerve biopsy performed at
the same time demonstrated a moderate chronic axonal
neuropathy with numerous degenerating myelinated and
unmyelinated fibers but no evidence of vasculitis. Bone
marrow studies demonstrated 45% eosinophils without
evidence of malignancy or atypia. She was treated with the
same initial therapeutic regimen as Case 1 which included
IV corticosteroids and oral cyclophosphamide, followed by
mycophenolate mofetil (MMF) 2 grams/day.
Extensive questioning did not disclose the use of any
other over-the-counter products, including L-tryptophan,
Figure 2: Case 2. Cryostat section of muscle stained with
hematoxylin and eosin demonstrates an intramuscular arteriole
with mural infiltrate of lymphocytes and histiocytes and luminal
obliteration. No eosinophils were present; however, the biopsy was
obtained one week after IV corticosteroid administration.
recent use of leukotriene inhibitors, or any other new
medication. However, both patients recalled the use of a
new brand of probiotics described as an “extra-strength
concentration” in a boxed blister pack, purchased over-
the-counter in a Philadelphia metropolitan area pharmacy.
Unfortunately we were unable to unequivocally identify the
specific brand. None of the patients had gastrointestinal
complaints, but they used the probiotic to “improve their
immune system”.
Both patients were negative for FIP-1 (PDGF) mutations
which are commonly present in myeloproliferative forms
of eosinophilic syndrome. Furthermore, there were no
abnormalities detected by peripheral blood or bone marrow
flow cytometry, nor abnormal PDGF-related translocations
or other cytogenetic abnormalities. None of the patients
developed respiratory symptoms or had pulmonary infil-
trates on high-resolution chest-computed tomography scans.
Response to IV corticosteroids followed by immuno-
suppressive therapy was optimal in both cases, with rapid
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resolution of peripheral blood eosinophilia and of the
generalized symptoms. Although there was some degree
of neurological improvement, to date, both patients have
remained with permanent motor and sensory deficits in the
lower extremities requiring orthotic devices for ambulation.
3. Discussion
We describe here the clinical manifestations and exten-
sive laboratory, histopathologic, and radiological studies of
two patients who developed an abrupt onset of a severe
eosinophilic syndrome with prominent constitutional symp-
toms, necrotizing vasculitis, and mononeuritis multiplex,
occurring in close temporal association with the ingestion of
a probiotic supplement. Both of the patients were initially
diagnosed with Churg-Strauss vasculitis, and one of them
fulfilled the American College of Rheumatology diagnostic
criteria proposed for Churg-Strauss [7]. There was histo-
logical evidence of an eosinophilic necrotizing vasculitis in
one of the cases, whereas the second case showed vasculitis
without tissue eosinophils. It is very likely that the absence of
eosinophils in the tissue vasculitic infiltrate in the second case
is related to the IV corticosteroid therapy which was insti-
tuted prior to the biopsy. However, a more detailed analysis
taking into consideration the severity and sudden onset of
their general symptoms, absence of prior history of asthma
in one of the patients (and nonactive mild episodic asthma in
the other), absence of lung parenchymal involvement in both
patients, negative ANCA (immunofluorescence and ELISA
MPO/PR3 antibodies), marked eosinophilia (above 50% of
the total WBC in both patients), and the close temporal
association with consumption of a probiotic agent leads us
to conclude that their disease was induced by the ingestion
of a foreign agent presenting as an eosinophilic syndrome.
Thus, we believe that these two cases may represent a
novel eosinophilic clinical entity distinct fromChurg-Strauss
syndrome.
The cases presented diﬀer from eosinophilia myalgia syn-
drome (EMS) because of the absence of skin edema or fibro-
sis, the lack of a history of L-tryptophan ingestion, and the
presence of acute neurological involvement as opposed to the
subacute or chronic course of neurological manifestations
typically described in EMS [8].
Numerous severe eosinophilic syndromes related to
unsuspected immunogenic substances have been well
described in the past presenting initially as either clusters
or isolated cases which subsequently reached epidemic
proportions. The Spanish toxic oil and EMS are good
examples [8, 9]. Although it was generally accepted that the
EMS epidemic had disappeared following the withdrawal of
the contaminated L-tryptophan containing preparations, a
nonepidemic case of EMS has very recently been reported
[10]. In both disorders, the initial presentation of isolated
or clustered cases associated with either a nonregulated
contaminated food or dietary supplement delayed the recog-
nition of the etiological agent and the prevention of new
cases [11]. Both of the patients described here presented to
medical attention in the same month, and apparently both
acquired the suspected agent at approximately the same time
raising epidemiological concerns of additional unreported or
undiagnosed cases.
Prior experience in unveiling the etiology of the eosino-
philic syndromes has shown that a high index of suspicion
is required. The description of these two cases may allow the
recognition of similar cases and remind the medical commu-
nity that the widespread use of agents seemingly considered
to be beneficial and free of side eﬀects may occasionally have
serious consequences. In this paper, we welcome government
eﬀorts focused on the establishment and enforcement of
regulations promoting “good manufacturing practices” for
dietary supplements.
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